2013 Report on the Japanese HIV Drug Market - Forecasts to 2022
(M2 PressWIRE Via Acquire Media NewsEdge) Dublin - Research and Markets (http://www.researchandmarkets.com/research/l4jfdl/pharmapoint_hiv) has announced the addition of the "2013 Report on the Japanese HIV Drug Market - Forecasts to 2022" report to their offering.
The treatment algorithm in HIV has characteristically involved multiple drug regimens designed to tackle the virus on different levels. In the recent past, simplified dosing regimens through the emergence of single tablet regimens (STRs) or fixed dose combination (FDC) therapies have become increasingly popular amongst physicians and patients alike by increasing clinical efficacy thresholds and enabling patient compliance. This can be explained by the low prevalence and incidence rates of HIV in Japan.
Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most infected individuals. Antiretroviral treatment not only reduces the viral load and reconstitutes immune function, but also decreases infection incidence rates by limiting viral transmission
The Japanese market is different from the other major markets in that STR use has not yet been introduced. For example, Atripla, which is the market leader in the US and Europe, is not currently licensed in Japan. However, the first integrase-based STR, Gilead's Stribild, which was approved by the FDA in August 2012, might be launched in Japan by the end of 2013 or at the beginning of 2014. Japan Tobacco, through its research alliance with Gilead, filed for market approval of elvitegravir in December 2012 with the Japanese Ministry of Health, Labour and Welfare. It is forecasted that ViiV will adopt a similar approach to launch the novel INI-based inhibitor dolutegravir and 572-Trii into the Japanese market.
Key Topics Covered:
1 List of Tables and Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Opportunity and Unmet Need
7 Pipeline Assessment
8 Market Outlook
For more information visit http://www.researchandmarkets.com/research/l4jfdl/pharmapoint_hiv
Research and Markets,
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716
Sector: Pharmaceuticals (http://www.researchandmarkets.com/categories.asp?cat_id=16&campaign_id=l4jfdl)
(c) 2014 M2 COMMUNICATIONS
[ InfoTech Spotlight's Homepage ]